Quotables
"This is the patent age of new inventions for killing bodies, and for saving souls. All propagated with the best intentions."
Lord Byron ;
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7705013 | Use of canthin-6-one, plant extracts containing same and derivatives thereof in the treatment of trypanosomiases A method of treating trypanosomiasis in a mammal, which entails administering to a mammal in need thereof an effective amount of medicinal producting comprising a plant extract comprising one or more compounds of formula (I). ... | 04/27/2010 |
| 7666877 | Ergoline derivatives Disclosed are ergoline derivatives, Formula (I), wherein either each of R1 and R2, independently, is H; optionally R10 and/or R11-substituted-phenyl or -phenyl-C1-4alkyl; optionally R10 and/or R1... | 02/23/2010 |
| 7632843 | Treatment of psychostimulant addiction The present invention belongs to the field of pharmaceutical industry and relates to a new method for the treatment of psychostimulant addiction, in particular cocaine addiction, or pharmaceutically acceptable acid addition salts thereof, with a therapeutically effe... | 12/15/2009 |
| 7622476 | Methods of using 1-allyl ergot alkaloid derivatives to treat migraines This invention relates to 1-allyl ergot alkaloids and their derivatives with selective antagonistic properties to 5-HT2 receptors for the prevention of, and relief from, migraine-related headache, Parkinson's disease, disorders of the thrombocyte function... | 11/24/2009 |
| 7531551 | Polymorphs of cabergoline Provided are new crystalline Forms VIII, IX, XI, XII, XIV, XV, XVI, XVII, and XVIII of cabergoline. Also provided are novel processes for preparation of cabergoline Form I, Form II, Form VII, and amorphous cabergoline. ... | 05/12/2009 |
| 7342028 | Medical use for tachykinin antagonists The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharm... | 03/11/2008 |
| 7309497 | Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients The invention relates to novel pharmaceutical compositions for the systemic administration of pharmacologically active ingredients. The invention relates in particular to an injectable pharmaceutical composition comprising (a) a pharmacologically active ingredient i... | 12/18/2007 |
| 7285553 | Serotonergic 5HTreceptor compounds for treating ocular and CNS disorders Compounds with 5HT7 receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for... | 10/23/2007 |
| 7258871 | Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparatio... | 08/21/2007 |
| 7201922 | Orodispersible solid pharmaceutical form The subject of the invention is an orodispersible solid pharmaceutical form characterized in that it comprises: granules consisting of lactose and starch which have been codried; at least one active substance.... | 04/10/2007 |
| 7196059 | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith Pharmaceutical compositions that include insulin, an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component or a bile salt component without a fatty acid component are described. The insulin drug is covalently coupled to an oligomeric moi... | 03/27/2007 |
| 7166617 | Cyclic amide derivatives Novel compounds represented by the following formula (I) that act as a ligand to sigma receptor/binding cite and a medicament comprising the same as an active ingredient: wherein X represents an alkyl group, an a... | 01/23/2007 |
| 7157102 | Multi-layered microcapsules and method of preparing same A multi-layered microcapsule containing one or more active ingredients and process for preparing the same is disclosed. The multi-layered microcapsule comprises an inner solid microparticle core, typically composed of a biodegradable polymer, and having one or more ... | 01/02/2007 |
| 7144843 | Pest controllers An objective of the present invention is to provide a harmful organism control agent that possesses excellent control effect against harmful organisms and can be safely used. The present invention provides a compound of formula (1) or a salt thereof. The present inv... | 12/05/2006 |
| 7141582 | Method for enhancing mutant enzyme activities in Gaucher disease Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method ... | 11/28/2006 |
| 7122203 | Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof The present invention is directed to pharmaceutical formulations containing 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxypheny)benzo[b]thiophene or a salt thereof; stabilized to oxidation or other forms of decomposition by incorporation of a stabili... | 10/17/2006 |
| 7118873 | Polynucleotides encoding cellular transporters and methods of use thereof This disclosure encompasses the Indy gene, polypeptides encoded by the Indy gene and fragments thereof. This disclosure also encompasses homologs of the Indy gene both from Drosophila and other organisms. In addition, this disclosure encompasses the use of In... | 10/10/2006 |
| 7108866 | Chronotherapeutic diltiazem formulations and the administration thereof A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of D... | 09/19/2006 |
| 7084114 | Mixtures of insulin drug-oligomer comprising polyalkylene glycol A mixture of conjugates in which each conjugate in the mixture comprises an insulin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugate... | 08/01/2006 |
| 7084121 | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. M... | 08/01/2006 |
| 7081455 | Substituted heterocycle fused gamma-carbolines The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, ... | 07/25/2006 |
| 7071234 | Methods of treating or preventing erectile dysfunction Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic... | 07/04/2006 |
| 7067557 | Methods of treating androgen deficiency in men using selective antiestrogens The administration of antiestrogens to men suffering a relative androgen deficiency stimulates the body's production of testosterone leading to a correction of the deficiency. For example, male menopause, loss of cognitive function, insulin resistance, type 2 diabet... | 06/27/2006 |
| 7060704 | Serotonergic 5HTreceptor compounds for treating ocular and CNS disorders Compounds with 5HT7 receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for... | 06/13/2006 |
| 7048917 | Fat-binding polymers The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. Th... | 05/23/2006 |
| 7041320 | High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence Methods and compositions to induce opioid drug independence in opioid drug dependent individuals comprising administering opioid agonists and/or antagonists encapsulated in biodegradable polymer microspheres in a dosage formulation. ... | 05/09/2006 |
| 7026483 | Forms of cabergoline The invention provides methods for preparing amorphous physical form of cabergoline, and solvate form A of cabergoline useful in the preparation of the first mentioned physical form. A method for treating a prolactin disorder with medicaments prepared from amorphous... | 04/11/2006 |
| 6974839 | Method of delaying ejaculation The invention provides a method of delaying ejaculation. The method comprises administering an effective amount of a tramadol material to a human male prior to sexual intercourse. The method is particularly useful for treating premature ejaculation. ... | 12/13/2005 |
| 6960579 | Serotonergic 5HTreceptor compounds for treating ocular and CNS disorders Compounds with 5HT7 receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for... | 11/01/2005 |
| 6953854 | Process for preparing crystalline Form I of cabergoline A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals. A new solvate form V of... | 10/11/2005 |
| 6916829 | Method for enhancing mutant enzyme activity in gaucher disease Method for enhancing in a mammalian cell the activity of an enzyme associated with Gaucher Disease by administering a competitive inhibitor of glucocerebrosidase in an amount effective to enhance the activity of the enzyme. Preferred compounds for use in the method ... | 07/12/2005 |
| 6906040 | Method for reducing toxicity of combined chemotherapies Compositions and methods are provided for use in the treatment of cancer. ... | 06/14/2005 |
| 6849619 | Substituted pyridoindoles as serotonin agonists and antagonists The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, ... | 02/01/2005 |
| 6844353 | Fungicidal properties of sampangine and its analogs to agriculturally important fungal plant pathogens It has been found that sampangine and related analogs such as benzo[4,5]sampangine, 4-bromosampangine and 4-methoxysampangine may be used as effective fungicidal agents for plants. Fungicidal plant compositions and methods of using the materials for such a purpose a... | 01/18/2005 |
| 6838456 | Condensed pyridoindole derivatives Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents. ... | 01/04/2005 |
| 6800635 | Crystalline form II of cabergoline Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from s solution of raw cabergoline in an organic solvent at low temperatures or submitting to a s... | 10/05/2004 |
| 6777405 | Detection and treatment of duplex polynucleotide damage Duplex polynucleotides containing damage or errors are detected with hindered intercalating compounds which are capable of intercalating only in the presence of such damage or error. Conditions characterized by the presence of polynucleotide errors or damage are tre... | 08/17/2004 |
| 6777406 | Substituted pyrroloquinolines and pyridoquinolines as serotinin agonists and antagonists The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein is R1, R6a, R6b, R7 | 08/17/2004 |
| 6727242 | Pharmacological treatment for sleep apnea The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess serotonin-related pharmacological activity. ... | 04/27/2004 |
| 6699852 | Substituted pyridoindoles as serotonin agonists and antagonists The present invention is directed to certain novel compounds represented by structural Formula (I) ##STR1## or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9... | 03/02/2004 |
